The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
Abstract
Purpose: Vascular endothelial growth factor (VEGF) plays an important role in the biology of ovarian cancer (OC). Inhibitors of VEGF suppress tumor growth in OC models. Metronomic chemotherapy, defined as frequent administration of low doses of cytotoxic chemotherapy, suppresses tumor growth, possibly by inhibiting angiogenesis. A phase II trial was conducted to evaluate the antitumor activity and adverse effects of bevacizumab and metronomic oral cyclophosphamide in women with recurrent OC. Patients and Methods: Patients with measurable disease and prior treatment with a platinum-containing regimen were eligible. Up to two different regimens for recurrent disease were allowed. Treatment consisted of bevacizumab 10 mg/kg intravenously every 2 weeks and oral cyclophosphamide 50 mg/d. The primary end point was progression-free survival at 6 months. Plasma levels of VEGF, E-selectin, and thrombospondin-1 were obtained serially. Results: Seventy patients were enrolled. The probability of being alive and progression free at 6 months was 56% (± 6% SE). A partial response was achieved in 17 patients (24%). Median time to progression and survival were 7.2 and 16.9 months, respectively. The most common serious toxicities were hypertension, fatigue, and pain. Bevacizumab-related toxicities included four episodes of gastrointestinal perforation or fistula, two episodes each of CNS ischemia and pulmonary hypertension, and one episode each of gastrointestinal bleeding and wound healing complication. There were three treatment-related deaths. Levels of VEGF, E-selectin, and thrombospondin-1 were not associated with clinical outcome. Conclusion: The combination of bevacizumab and metronomic cyclophosphamide is active in recurrent OC. Further study of this combination is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
Liotta, L. A., Steeg, P. S., & Stetler-Stevenson, W. G. (1991) · Cell · doi:10.1016/0092-8674(91)90642-c · Cited by 2,720
Cannistra, S. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041842 · Cited by 2,129
Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,608
Self-citationBrowder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,543
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Burger, R. A., Sill, M. W., Monk, B. J., Greer, B. E., & Sorosky, J. I. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5345 · Cited by 882
Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
Hanahan, D., Bergers, G., & Bergsland, E. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9872 · Cited by 865
Role of vascular endothelial growth factor in the regulation of angiogenesis
Ferrara, N. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00610.x · Cited by 731
Bookman, M. A., Darcy, K. M., Clarke-Pearson, D., Boothby, R. A., & Horowitz, I. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.104 · Cited by 598
Clinical Implications of Circulating Angiogenic Factors in Cancer Patients
Poon, R. T.-P., Fan, S.-T., & Wong, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1207 · Cited by 587
Colleoni, M., Rocca, A., Sandri, M. T., Zorzino, L., Masci, G., Nolè, F., Peruzzotti, G., Robertson, C., Orlando, L., Cinieri, S., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf013 · Cited by 496
Maximally Selected Chi Square Statistics
Miller, R., & Siegmund, D. (1982) · Biometrics · doi:10.2307/2529881 · Cited by 490
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
Bocci, G., Francia, G., Man, S., Lawler, J., & Kerbel, R. S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2135406100 · Cited by 414
Redefining the Target: Chemotherapeutics as Antiangiogenics
Miller, K. D., Sweeney, C. J., & Sledge, G. W. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1195 · Cited by 395
Expression of Angiogenesis-Related Genes and Progression of Human Ovarian Carcinomas in Nude Mice
Yoneda, J., Kuniyasu, H., Price, J. E., Bucana, C. D., Fidler, I. J., & Crispens, M. A. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.6.447 · Cited by 375
Vascular endothelial growth factor expression in early stage ovarian carcinoma
Paley, P. J., Staskus, K. A., Gebhard, K., Mohanraj, D., Twiggs, L. B., Carson, L. F., & Ramakrishnan, S. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970701)80:1<98::aid-cncr13>3.0.co;2-a · Cited by 364
Yamamoto, S., Konishi, I., Mandai, M., Kuroda, H., Komatsu, T., Nanbu, K., Sakahara, H., & Mori, T. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.537 · Cited by 356
Goff, B. A., Sainz de la Cuesta, R., Muntz, H. G., Fleischhacker, D., Ek, M., Rice, L. W., Nikrui, N., Tamimi, H. K., Cain, J. M., Greer, B. E., et al. (1996) · Gynecologic Oncology · doi:10.1006/gyno.1996.0065 · Cited by 352
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O’Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.2 · Cited by 344
Man, S., Bocci, G., Francia, G., Green, S. K., Jothy, S., Hanahan, D., Böhlen, P., Hicklin, D. J., Bergers, G., & Kerbel, R. S. (2002) · PubMed · Cited by 314
Schilder, R. J., Sill, M. W., Chen, X., Darcy, K. M., Decesare, S. L., Lewandowski, G., Lee, R. B., Arciero, C. A., Wu, H., & Godwin, A. K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0462 · Cited by 258
Vascular permeability factor gene expression in normal and neoplastic human ovaries.
Olson, T. A., Mohanraj, D., Carson, L. F., & Ramakrishnan, S. (1994) · PubMed · Cited by 257
Klement, G. L., Huang, P. H., Mayer, B., Green, S. K., Man, S., Böhlen, P., Hicklin, D. J., & Kerbel, R. S. (2002) · PubMed · Cited by 243
Potentiation of cytotoxic cancer therapies by TNP‐470 alone and with other anti‐angiogenic agents
Teicher, B. A., Holden, S. A., Ara, G., Sotomayor, E. A., Huang, Z. D., Chen, Y., & Brem, H. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910570624 · Cited by 231
GORDON, A. N., FINKLER, N., EDWARDS, R. P., GARCIA, A. A., CROZIER, M., IRWIN, D. H., & BARRETT, E. (2005) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2005.00137.x · Cited by 221
Self-citationAbu‐Jawdeh, G. M., Faix, J. D., Niloff, J. M., Tognazzi, K., Manseau, E. J., Dvorak, H. F., & Brown, L. (1996) · PubMed · Cited by 202
Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma
Shen, G. H., Ghazizadeh, M., Kawanami, O., Shimizu, H., Jin, E., Araki, T., & Sugisaki, Y. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1228 · Cited by 201
du Bois, A., Weber, B., Rochon, J., Meier, W., Goupil, A., Olbricht, S., Barats, J.-C., Kuhn, W., Orfeuvre, H., Wagner, U., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2938 · Cited by 196
Hamano, Y., Sugimoto, H., Soubasakos, M. A., Kieran, M., Olsen, B. R., Lawler, J., Sudhakar, A., & Kalluri, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3126 · Cited by 185
Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo.
Bello, L., Carrabba, G. G., Giussani, C. G., Lucini, V., Cerutti, F., Scaglione, F., Landré, J., Pluderi, M., Tomei, G., Villani, R. M., et al. (2001) · PubMed · Cited by 180
Nagy, J. A., Morgan, E. S., Herzberg, K. T., Manseau, E. J., Dvořàk, A. M., & Dvorak, H. F. (1995) · PubMed · Cited by 163
De Placido, S., Scambia, G., Di Vagno, G., Naglieri, E., Lombardi, A. V., Biamonte, R., Marinaccio, M., Cartenì, G., Manzione, L., Febbraro, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.088 · Cited by 161
Takahashi, N., Haba, A., Matsuno, F., & Seon, B. K. (2001) · PubMed · Cited by 150
Ramaswamy, B., ELIAS, A. D., Kelbick, N., Dodley, A., Morrow, M., Hauger, M., Allen, J., Rhoades, C. A., Kendra, K. L., Chen, H. X., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2603 · Cited by 116
Self-citationBuckstein, R. J., Kerbel, R. S., Shaked, Y., Nayar, R., Foden, C., Turner, R. A., Lee, C. R., Taylor, D., Zhang, L., Man, S., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0474 · Cited by 110
Phase II Trial of Carboxyamidotriazole in Patients With Relapsed Epithelial Ovarian Cancer
Hussain, M. M., Kotz, H. L., Minasian, L. M., Premkumar, A., Sarosy, G., Reed, E., Zhai, S., Steinberg, S. M., Raggio, M., Kulpa, V., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.136 · Cited by 92
Tumour angiogenesis: pathophysiology and clinical significance
Lichtenbeld, H., VANDAMMIERAS, M., & Hillen, H. F. P. (1996) · The Netherlands Journal of Medicine · doi:10.1016/0300-2977(95)00117-4 · Cited by 18
Bassukas, I. D., Vester, G., & Maurer‐Schultze, B. (1990) · Virchows Archiv B Cell Pathology Including Molecular Pathology · doi:10.1007/bf02899411 · Cited by 9
Cited by
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
Self-citationKerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 1,948
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Ovarian Cancer Development and Metastasis
Lengyel, E. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100105 · Cited by 1,672
Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., Sorio, R., Vergote, I., Witteveen, P., Bamias, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4489 · Cited by 1,622
Metadata
- Authors
- Garcia, A. A., Hirte, H., Fleming, G., Yang, D., Tsao-Wei, D. D., Roman, L., Groshen, S., Swenson, S., Markland, F., Gandara, D., Scudder, S., Morgan, R., Chen, H., Lenz, H.-J., & Oza, A. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-01-01
- Volume
- 26
- Issue
- 1
- Pages
- 76-82
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2018929154
- Cited by
- 547
- References
- 44
- FWCI
- 55.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.